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1. INTRODUCTION
jj Allergic bronchopulmonary aspergillosis (ABPA), the most common form of allergic bron-
chopulmonary mycosis, is a complex specific immunological response to antigens of 
Aspergillus species colonizing the bronchi of CF patients (see also Chapter “Fungi”). 
Recurrent episodes of bronchial obstruction, inflammation and mucoid impaction lead to 
bronchiectasis, pulmonary infiltrates and fibrotic changes.
jj The prevalence of ABPA in CF is 2 to 15 % but the rates of colonization (up to 75 % when 
new molecular and selective culture techniques are used) and of sensitization (~ 30 %) 
are much higher. As the pathogenesis of ABPA remains incompletely understood, it is 
still unclear why some colonized CF patients become sensitized and others not, and why 
some sensitized CF patients develop ABPA and others not. 
jj Factors associated with ABPA in CF include 
js age (peaking in adolescence) 
js atopy
js severity of lung disease 
js colonization with Pseudomonas aeruginosa
jj The diagnostic criteria used in non-CF patients with ABPA cannot be applied to CF patients 
with ABPA, as bronchiectasis is a pathological feature of both CF and ABPA.
2. DIAGNOSIS
jj Pursuing diagnosis when ABPA is suspected or by a screening approach in subjects at 
risk, such as CF patients, is very important because :
js this condition responds to steroids and
js its early detection and treatment may decrease the risk of evolution to irreversible fibrotic 
changes
jj There is not a specific single diagnostic test for ABPA but diagnosis is traditionally based 
on the combination of clinical, radiological and immunological criteria. In CF, recognizing 
and diagnosing ABPA is difficult and often delayed because some criteria overlap 
with CF itself (e.g. presence of bronchiectasis). Therefore, diagnostic criteria used in 
non-CF patients with ABPA cannot be applied to CF patients with ABPA.
jj Due to these difficulties, a Cystic Fibrosis Foundation Consensus Conference has identi-
fied diagnostic (Table 1) and screening criteria (Table 2) for ABPA in CF. 
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 Table 1: Diagnostic criteria of ABPA in CF1
Classic case
–  Acute or subacute clinical deterioration (cough, wheeze, exercise intolerance, exercise- 
induced asthma, decline in pulmonary function, increased sputum) not attributable to another 
etiology
–  Serum total IgE > 1000 IU/ml (> 2400 ng/ml), unless the patient is receiving systemic  
corticosteroids; if so, retest when steroid treatment is discontinued
–  Immediate skin test reactivity to Aspergillus species or in vitro presence of serum IgE antibody 
to A. fumigatus
–  Precipitating antibodies to A. fumigatus or serum IgG antibody to A. fumigatus
–  New or recent abnormalities on chest radiograph (infiltrates or mucus plugging) or chest CT 
(bronchiectasis) that have not cleared with antibiotics and standard physiotherapy
Minimal diagnostic criteria
–  Acute or subacute clinical deterioration (cough, wheeze, exercise intolerance, exercise- 
induced asthma, decline in pulmonary function, increased sputum) not attributable to another 
etiology
–  Total serum IgE > 500 IU/ml (> 1200 ng/ml). If ABPA is suspected and the total IgE level is 
200-500 IU/ml, repeat testing in 1-3 months is recommended. If the patient is taking steroids, 
repeat when steroid treatment is discontinued.
–  Immediate skin test reactivity to Aspergillus species or in vitro presence of serum IgE antibody 
to A. fumigatus
–  One of the following : 
  a) precipitins to A. fumigatus or in vitro demonstration of IgG antibody to A. fumigatus; or 
  b)  new or recent abnormalities on chest radiograph (infiltrates or mucus plugging) or chest CT 
(bronchiectasis) that have not cleared with antibiotics and standard physiotherapy.
Note: Although it may be present in some cases, eosinophilia is not one of the diagnostic crite-
ria of ABPA in CF, as it is not a specific finding in this context.
 Table 2: Screening criteria for ABPA in CF1
Maintain a high level of suspicion for ABPA
Determine the total serum IgE concentration annually: 
–  If the total serum IgE concentration is > 500 IU/ml, → determine immediate cutaneous 
reactivity to A. fumigatus or use an in vitro test for IgE antibody to A. fumigatus → if results are 
positive, consider diagnosis on the basis of minimal criteria.
–  If the total serum IgE concentration is 200-500 IU/ml → repeat measurement if there is 
increased suspicion for ABPA, such as disease exacerbation, and perform further diagnostic 
tests (immediate skin test reactivity to A. fumigatus, in vitro test for IgE antibody to A. fumiga-
tus, A. fumigatus precipitins, or serum IgG antibody to A. fumigatus, and chest radiography).
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3. TREATMENT 
jj Figure 2 presents a therapeutic strategy that may be applied for ABPA in CF patients and 
Table 3 summarizes information on agents used for ABPA.
jj Systemic corticosteroids: the few studies on ABPA in CF patients are small and non-
controlled. Nevertheless, these limited data suggest that steroids are efficient. 
js Although precise doses and treatment duration remain unclear, currently oral corticos-
teroids are considered the mainstay treatment of ABPA. 
2.1 Recombinant antigens for the diagnosis of ABPA
jj For therapeutic reasons, ABPA has to be clearly distinguished from sensitization to 
Aspergillus. 
jj A panel of recombinant antigens including Asp f2, Asp f4 and Asp f6 may allow the two 
conditions to be distinguished and thus it may be a useful diagnostic tool. 
js Serological investigations using Asp f4 and Asp f6 showed that specific IgE against 
these two allergens are detected exclusively in sera of patients with ABPA. However, 
larger studies are required to fully assess the diagnostic value of these new antigens.
2.2 Imaging 
jj CT is more sensitive than chest radiography for the detection of ABPA abnormalities 
(Figure 1).
jj Radiological assessment of ABPA in patients with CF is very limited by overlapping fin-
dings in the two diseases.
jj The only reported imaging abnormality seen in ABPA and not in CF is the presence of 
high-attenuation mucus plugs, but it is not always present. 
Figure 1: ABPA in a 40 year old CF female patient (delF508/R851L) 
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Figure 2: Therapeutic strategy for ABPA in CF patients 
Exclude environmental mold exposure
Good response*1 Attempt to taper corticosteroids 
within 4 months
Antifungal agent for at least 4 months
Attempt to taper corticosteroids in 4 months
Poor response Good response*
1
Poor response
Delay tapering and consider adding itraconazole
Poor response despite itraconazoleTDM within
the desired range (trough level >0.5mg/L)*1
*1In general terms, clinical response is considered satisfactory if there is an  
improvement of symptoms and PFTs (e.g. >50% back to baseline). Subsequent 
measurements of IgE would be expected to show decreasing levels.
*2Monthly IV pulse methylprednisolone may be considered in dicult-to-treat ABPA
with severe side eects to conventional oral prednisone
*3Although data is limited, this order is based on  currently published evidence.
Abbreviations: PCP=Pneumocystis pneumonia, PFTs=pulmonary function tests, 
TDM=therapeutic drug monitoring
In 2-4 weeks: Clinical status and PFTs 
First TDM in 5-7 days
In 2 weeks and thereafter: monitor clinical status, PFTs, total IgE, 
antifungal TDM, liver function. Consider PCP prophylaxis if 
prednisone ≥20mg/day for >1month.
Oral prednisone
Bone prophylaxis, surveillance of glucose levels,
adjustment of insulin dose if applicable
Poor response despite voriconazoleTDM within
the desired range (trough level 2-5 mg/L)*1
Good response*1
-Increase oral corticosteroids/delay tapering*2
-Perform antifungal susceptibility testing 
-Consider switching to voriconazole
-Maximize the dose of voriconazole balancing clinical
response, toxicity and TDM results
-Confirm treatment compliance
-Apply strategies to improve itraconazole absorption
-Maximize the dose of itraconazole balancing clinical
response, toxicity and TDM results
Consider*3:
Omalizumab
Inhaled amphotericin
Oral posaconazole
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js Monthly IV pulse of methylprednisolone has been administered in some patients who 
had difficult to treat ABPA and severe side effects to conventional oral prednisone. 
jj Antifungal therapy: steroids have no effect on Aspergillus burden. Several studies 
showed that antifungal therapy seems to be effective and steroid-sparing, but these stu-
dies included small numbers of patients and very few patients with CF.
js As for steroids, precise doses and duration of the antifungal therapy remain unclear. 
Pragmatically and by analogy to the recommended treatment of ABPA in non-CF pa-
tients, when a combination of oral corticosteroids and antifungal therapy is used, the 
recommended treatment duration is at least 4 months. 
js Regarding the choice of the antifungal agent, although no comparative efficacy or safety 
studies exist in CF patients with ABPA usually itraconazole is the 1st choice. Although of 
uncertain clinical usefulness, antifungal susceptibility testing may be considered in se-
lected cases (e.g. refractory, difficult to treat cases) to aid the choice of antifungal agent.
jj Omalizumab (Xolair®): is a recombinant monoclonal anti-IgE antibody that has been used 
in patients with moderate to severe allergic asthma as a corticosteroid-sparing agent. 
Since elevated IgE is a central finding in ABPA, omalizumab has been used to provide 
symptom control and allow corticosteroid tapering in patients with poor response to the 
conventional ABPA treatment. 
js Case-reports in CF pediatric patients with ABPA, suggest that omalizumab may be as-
sociated with improved lung function, reduced frequency of respiratory symptoms and 
decreased use of systemic corticosteroids. 
js For adult CF patients, data on treatment efficacy and safety are extremely limited. 
jj Inhaled corticosteroids: Given the limited information available, inhaled corticoste-
roids cannot be recommended in the treatment of ABPA in CF or for prevention of fibrotic 
changes. However, they may be considered for the asthmatic component of ABPA.
Note: itraconazole may enhance the adrenal suppressant effect of inhaled corticosteroids.
jj Environmental manipulation (modification of environmental mold exposure): may be 
considered in refractory cases.
4. MONITORING OF TREATMENT EFFICACY
jj Generally, when the therapeutic response is good, total IgE is expected to decrease after 
1-2 months of treatment, eosinophilia (if initially present) to resolve, and PFTs and radiolo-
gical abnormalities to improve. Imaging should not worsen under therapy. 
jj In addition to the evaluation of symptoms and PFTs, serial measurements of total serum 
IgE are used to monitor treatment efficacy
js During treatment for ABPA: IgE levels should be measured every 1-2 months. 
js In ABPA remission: IgE levels should be measured every 3-6 months
Note (for patients receiving omalizumab): the majority of commercially available IgE assays 
measure free as well as omalizumab-bound IgE. At the moment of writing the role of total 
serum IgE to monitor omalizumab treatment is not established. 
jj Follow-up chest imaging should be considered in a case-by-case basis balancing treat-
ment implications and radiation exposure. 
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 Table 3: Pharmaceutical agents used for ABPA
Drug Route Dose Duration Comment
Systemic corticosteroids
Prednisone Oral 0.5-1 mg/kg/day (max  
60 mg/day) for 2-4 weeks 
and then consider  
tapering
Attempt to taper 
over 4 months to 
the lowest dose 
associated with 
no rebound in IgE, 
clinical symptoms, 
eosinophilia or new 
infiltrates
–  After prednisone initiation, follow-up patients 
at least every two weeks for the first month to 
assess response to treatment. 
–  Monitor and treat corticosteroid-induced 
adverse effects such as diabetes, bone loss, 
infections*1, adrenal suppression
Methylprednisolone IV 10-15 mg/kg/day (max  
1g) for 3 consecutive  
days once a month 
Until clinical and 
laboratory resolu-
tion of ABPA (6-10 
courses in  
the literature)
–  It may be considered for selected cases 
presenting severe adverse effects to oral 
corticosteroids. 
–  It seems to be an effective and relatively safe 
alternative in this context; however, no long-
term efficacy and safety data are currently 
available in the literature.
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Antifungal agents*2
Itraconazole Oral 5mg/kg/day (max 600  
mg/day) 
When daily dose exceeds 
200 mg/day administer 
2x/day
At least 4 months –  1st choice antifungal agent
–  Monitor liver function tests, QT interval, drug 
interactions*3 
–  Strategies to increase absorption
  a)  Preferential use of the liquid formulation
  b)  For the liquid formulation: administration on an 
empty stomach, concomitant administration 
with a low pH drink (e.g. orange juice, coca 
cola) and avoidance/spaced use of acid-
blocking agents and proton pump inhibitors.
  c)  For capsules: administration with food
–  TDM is required. In case of infratherapeutic le-
vels check treatment adherence and optimize 
absorption. If despite these measures levels 
remain infratheurapeutic see footnote*2
Voriconazole Oral Loading dose 400mg 
every 12h for two doses 
(optional) and then 200 
mg 2x/day
At least 4 months –  2nd choice antifungal agent (compared to itraco-
nazole, voriconazole has improved gastrointes-
tinal tolerance, better bioavailability but has 
been studied less, is associated more  often 
with adverse effects and is more expensive)
–  Monitor liver function tests, visual distur-
bances, photosensitivity, QT interval, drug 
interactions*3. Voriconazole may increase the 
dose concentration of PPIs and vice versa 
(pre-emptive omeprazole dose reduction by 
half should be considered in patients receiving 
omeprazole 40mg/day or greater)
–  TDM is required. In case of infratherapeutic 
levels check treatment adherence. If levels 
remain infratheurapeutic see footnote*2
–  Off-label use: before treatment initiation, 
obtain approval by patient’s insurance. 
(continued)
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Posaconazole Oral Tablets: Loading dose 
300mg every 12h for two 
doses and then 300mg 
1x/day
Solution: 600-800mg  
1x/day
Unknown –  Case report evidence (patients who did not 
tolerate itraconazole and voriconazole)
–  The bioavailability of solution and tablets is 
NOT similar! During prescription always spe-
cify if the dose refers to tablets or solution.
–  Monitor liver function tests, QT interval, drug 
interactions*3
–  TDM is required
–  Off-label use: before treatment initiation, 
obtain approval by patient’s insurance. 
Amphotericin B Nebulized2,3 Liposomal, L-AMB 
(AmBisome®): 
25 mg twice a day 3  
days/week in the first  
month and 2 days/week 
for several months fol-
lowed by 1 day/week
[50 mg in 12 ml of WFI 
(4mg/ml)→nebulisation 
using a dedicated jet 
nebulizer such as PARI-
Turboboy® over 15 min]
or
Conventional, AMB-d 
(Fungizone®): 10 mg  
twice a day 3days/week 
[50 mg of AMB-d dis-
solved in 10 ml of WFI 
(5mg/ml)→ nebulisation 
of 10mg (2ml) using a 
dedicated such as PARI-
Turboboy® over 15 min]
Unknown –  Limited evidence in ABPA (extensive use for 
antifungal prophylaxis in immunocompromized 
patients). Different forms, doses and adminis-
tration intervals have been used in the literature.
–  May be considered in difficult cases not tolerating 
oral antifungal agents or cases presenting 
 recurrent relapses that render tapering of corti-
costeroids and maintenance of remission difficult. 
In these cases, it may replace oral antifungals 
(switching) or added to the oral antifungal agent.
–  Risk of bronchospasm: perform spirometry 
before and after the first dose, administer 
bronchodilators before each dose, consider 
administering inhaled or nebulized budeso-
nide (0.5-1mg) after each dose.
–  Incompatible with NaCl: reconstitution with 
WFI only!
–  Reconstituted L-AMB can be stored for a 
maximum of 24h at 2-8°C.  
–  Reconstituted AMB-d can be stored for a 
maximum of 7 days at 2-8°C. 
–  Off-label use: before treatment initiation, 
obtain approval by patient’s insurance.
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Omalizumab SC Dose administered every 
2 or 4 weeks depending 
on patient weight and 
pre-treatment IgE  
levels*4
Unknown –  No randomized controlled studies in CF 
 patients with ABPA. 
–  The majority of commercially available IgE 
assays measure free as well as omalizu-
mab-bound IgE. At the moment of writing the 
role of total serum IgE to monitor omalizumab 
treatment is not established.
–  Observe patient for a minimum of 2 h following 
each  administration (hypersensitivity/anaphy-
lactoid reactions)
–  Off-label use: before treatment initiation, 
obtain approval by patient’s insurance. 
AMB-d=amphotericin B deoxycholate, L-AMB= liposomal amphotericin B, TDM=therapeutic drug monitoring, WFI=water for injection (see Chapter “Therapeutic drug 
monitoring”)
*1There is a lack of evidence for the role pneumocystis pneumonia (PCP) prophylaxis in this clinical context. In general terms, PCP prophylaxis with TMP/SMX should be considered 
in cases of prolonged treatment with high dose corticosteroids (e.g. ≥20mg/day of prednisone equivalent for >1month).
*2When itraconazole or voriconazole levels are consistently infratherapeutic in TDM, higher doses (e.g. itraconazole 200mg 3x/day or voriconazole 250-300mg 2x/day) may be 
considered in selected cases under close surveillance of TDM, clinical and biological toxicity. However this strategy is generally not recommended due to the risk of toxicity (variable 
absorption, non-linear pharmacokinetics and risk of accumulation).
*3Itraconazole and voriconazole inhibit CYP3A4. They may enhance the adrenal-suppressant effect of systemic or inhaled corticosteroids.
*4Dose calculator can be found in http://www.xolair.com/allergic-asthma/hcp/determining-the-dose.html and dose tables in http://www.xolair.com/allergic-asthma/hcp/deter-
mining-the-dose.html . These dosing recommendations were established for asthma patients. Pre-treatment IgE levels and patient weight are used to determine the dose. In these 
calculators, the upper limit of IgE before treatment is 700 IU/ml, which is usually lower to the IgE levels observed in CF patients with ABPA. In this case the administered dose of 
omalizumab should NOT exceed the maximal dose recommended for 700 IU/ml.
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